official website and that any information you provide is encrypted In the CARMELINA trial [see Clinical Studies (14)], acute pancreatitis was reported in 9 (0.3%) patients treated with TRADJENTA and in 5 (0.1%) patients treated with placebo. Randomization was stratified by baseline A1C (<8.5% vs 8.5%) and use of a prior oral antidiabetic drug (none vs monotherapy). Labels, All Index Uses Warnings Before taking Side effects Dosage Interactions What is linagliptin? Linagliptin is associated with only moderate reductions in HbA1c (by 0.4% and 0.69% in pivotal clinical studies)6,19 and is more suitable as add-on combination therapy than as single-agent treatment. Glycemic endpoints measured were A1C and FPG. Angioedema has also been reported with other dipeptidyl peptidase-4 (DPP-4) inhibitors. ), More about getting RSS News & Updates from DailyMed. In the TRADJENTA treatment arm of the CARMELINA trial [see Clinical Studies (14)], 2200 (63%) patients had renal impairment (eGFR <60 mL/min/1.73 m2). The labeling for linagliptin also includes data from a 24-week, randomized, double-blind, placebo-controlled study of linagliptin in combination with a sulfonylurea and metformin in patients with type-2 diabetes.6 The most commonly used sulfonylureas were glimepiride, 31%; glibenclamide, also known as glyburide (Micronase, Pfizer), 26%; and gliclazide (not available in the U.S.), 26%. However, the dose is usually not more than 25 mg of empagliflozin and 5 mg of linagliptin per day. The half-life of the metabolite was 10.8 hours. The results of CARMELINA, including the contribution of each component to the primary composite endpoint, are shown in Table 13. TRADJENTA has not been studied in patients with a history of pancreatitis. In fertility studies in rats, linagliptin had no adverse effects on early embryonic development, mating, fertility, or bearing live young up to the highest dose of 240 mg/kg (approximately 943-times the clinical dose based on AUC exposure). Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects. Figure 1 Kaplan-Meier: Time to First Occurrence of MACE in the CARMELINA Trial. Additional clinical trials are needed to further delineate the clinical profile of linagliptin in combination therapy. being able to get an erection, but not having it last long enough for sex. A randomized, placebo-controlled phase 3 study evaluated the effect of linagliptin monotherapy on glycemic control and on markers of beta-cell function in patients with inadequately controlled type-2 diabetes.19 A total of 503 patients were randomly assigned to linagliptin 5 mg (n = 336) or placebo (n = 167) once daily. During the same time period, severe hypoglycemic events, defined as an event requiring the assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions, were reported in 3 (4.4%) TRADJENTA-treated patients and 3 (4.6%) placebo-treated patients. All rights reserved. Acute pancreatitis, including fatal pancreatitis, has been reported in patients treated with TRADJENTA. 0597-0140-70, In combination with a sulfonylurea, linagliptin provided a statistically significant improvement from baseline in HbA1c levels, compared with placebo and a sulfonylurea at 18 weeks (adjusted means, 0.5% vs. 0.1%, respectively; P value not stated). Patients on an antihyperglycemic agent (52%) underwent a drug washout period of 4 weeks' duration. Citations, 5.2 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues, 7.1 Inducers of P-glycoprotein or CYP3A4 Enzymes, 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. The estimated background risk of major birth defects is 6% to 10% in women with pre-gestational diabetes with a HbA1c >7 and has been reported to be as high as 20% to 25% in women with HbA1c >10. government site. Linagliptin, a new DPP-4 inhibitor, offers another option for the treatment of inadequately controlled type-2 diabetes in patients who are already receiving metformin or a sulfonylurea. Placebo-corrected mean changes in fasting plasma glucose for the three linagliptin doses were 1.1 mmol/L (P = 0.002), 1.9 mmol/L (P < 0.0001), and 1.6 mmol/L (P = 0.0001), respectively.21, The incidence of AEs was similar for all treatment groups. Table 1 presents a comparison of the pharmacokinetic characteristics of the three available DPP-4 inhibitors.68,18, Key Pharmacokinetic Characteristics of the DPP-4 Inhibitors. TRADJENTA may be administered with or without food. The trial population included 17% patients 75 years of age and 62% patients with renal impairment defined as eGFR <60 mL/min/1.73 m2. The primary endpoint was the change from baseline in HbA1c after 24 weeks of treatment. Ring A, Port A, Graefe-Mody EU, et al. View NDC Code(s)NEW! Patients with a baseline A1C of 7% and 10% were included in the study including 709 patients with renal impairment (eGFR <90 mL/min), most of whom (n=575) were categorized as mild renal impairment (eGFR 60 to <90 mL/min). Therapy was stopped in patients on oral antihyperglycemic therapy for a period of 6 weeks (4 weeks followed by a 2-week, open-label, placebo run-in period). 1 INDICATIONS AND USAGE TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Files, Presentations Coadministration of TRADJENTA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.2)]. The usual dose is 5mg a day. Patients experienced relief of symptoms upon discontinuation of the medication. Disease-associated maternal and/or embryo/fetal risk. Plasma AUC of linagliptin increased in a less than dose-proportional manner in the dose range of 1 to 10 mg. Boehringer Ingelheim Pharmaceuticals, Inc. either owns or uses the CARMELINA and CAROLINA trademarks under license. Advise the patient to read the FDA-approved patient labeling (Medication Guide). Tradjenta is an oral diabetes medicine that helps control blood sugar levels. Patients were eligible to enter the trial if they were adults with type 2 diabetes, with HbA1c of 6.5% to 10%, and had either albuminuria and previous macrovascular disease (39% of enrolled population), or evidence of impaired renal function by eGFR and Urinary Albumin Creatinine Ratio (UACR) criteria (42% of enrolled population), or both (18% of enrolled population). In these 18- and 24-week studies, the changes from baseline in A1C were -0.4% and -0.4%, respectively, for those given TRADJENTA, and 0.1% and 0.3%, respectively, for those given placebo. A total of 730 patients with type 2 diabetes participated in 2 double-blind, placebo-controlled studies, one of 18 weeks' and another of 24 weeks' duration, to evaluate the efficacy and safety of TRADJENTA monotherapy. If you have had pancreatitis in the past, it is not known if you have a higher chance of getting pancreatitis while you take TRADJENTA. Side effects that you should report to your care team as soon as possible: Allergic reactionsskin rash, itching, hives, swelling of the face, lips, tongue, or throat. symptoms of heart failure --shortness of breath (even while lying down), swelling in your legs or feet, rapid weight gain. Sarashina A, Sesoko S, Nakashima M, et al. Take TRADJENTA exactly as your healthcare provider tells you to take it. No increase in QTc was observed with either the recommended dose of 5 mg or the 100 mg dose. Dosage form: oral tablet (5 mg) Drug class: Dipeptidyl peptidase 4 inhibitors Medically reviewed by Drugs.com on Mar 27, 2023. ***18-week study. being unable to get an erection at any time. A single dose of oral linagliptin ranging from 2.5 to 600 mg/day produced different t max values, from 0.7 to 3 h, . Patients with severe hepatic impairment (Child-Pugh class C) had comparable exposure of linagliptin in terms of AUC0-24 and approximately 23% lower Cmax compared with healthy subjects. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of B1 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. Randomization was stratified by baseline HbA1c (<8.5% vs 8.5%), and the previous use of antidiabetic drugs (metformin alone vs metformin plus one other OAD). Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type-2 diabetes: A randomized, double-blind, placebo-controlled study. Reductions in the pharmacokinetic parameters seen in patients with hepatic impairment did not result in reductions in DPP-4 inhibition. Sign up for free and stay up to date on research advancements, health tips, current health topics, and expertise on managing health. Other adverse reactions reported in clinical studies with treatment of TRADJENTA were hypersensitivity (e.g., urticaria, angioedema, localized skin exfoliation, or bronchial hyperreactivity) and myalgia. Del Prato S, Barnett AH, Huisman H, et al. Copy the URL below and paste it into your RSS Reader application. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see Clinical Considerations]. Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type-2 diabetes: A randomized, double-blind, placebo-controlled study. No adverse functional, behavioral, or reproductive outcome was observed in offspring following administration of linagliptin to Wistar Han rats from gestation day 6 to lactation day 21 at a dose 49-times the maximum recommended human dose, based on exposure. Executive summary: Standards of medical care in diabetes, 2011. See the end of this Medication Guide for a complete list of ingredients in TRADJENTA. If you do not remember until it is time for your next dose, skip the missed dose and go back to your regular schedule. The pharmacokinetics of linagliptin is similar in healthy subjects and in patients with type 2 diabetes. Linagliptin doses of 1 mg, 5 mg, and 10 mg provided mean, placebo-corrected reductions in HbA1c of 0.40% (P = 0.01 vs. placebo), 0.73% (P < 0.0001), and 0.67% (P < 0.0001), respectively. Warnings Linagliptin is used together with proper diet and exercise to treat high blood sugar levels caused by type 2 diabetes. conducted a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type-2 diabetes.23 A total of 707 patients were assigned to receive linagliptin 5 mg plus pioglitazone 30 mg once daily (n = 259) or placebo plus pioglitazone 30 mg once daily (n = 130). If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of TRADJENTA. ***Hypoglycemic incidence included both asymptomatic events (not accompanied by typical symptoms and plasma glucose concentration of 70 mg/dL) and symptomatic events with typical symptoms of hypoglycemia and plasma glucose concentration of 70 mg/dL. GLP-1 and GIP are involved in the physiological regulation of glucose homeostasis. Patients who failed to meet specific glycemic goals during the study were treated with pioglitazone rescue. View Labeling Archives, Boehringer Ingelheim Promeco, S.A. de C.V. 29 Linagliptin-metformin oral tablet is used along with diet and exercise to improve control of blood sugar levels in adults with type 2 diabetes. the unsubscribe link in the e-mail. For the remainder of the trial, dose adjustments in antidiabetic background therapy were allowed. The results show that the addition of the oral DPP-4 inhibitor linagliptin (5 mg once daily) to background glucose-lowering therapy provided a clinically meaningful HbA 1c reduction after 12 weeks that was sustained over 52 weeks. The https:// ensures that you are connecting to the Is usually not More than 25 mg of empagliflozin and 5 mg of per... The pharmacokinetic parameters seen in patients with type 2 diabetes glucose homeostasis 2 diabetes but having. Taking Side effects Dosage linagliptin dose 10mg levitra oral jelly What is linagliptin has also been reported with other peptidase-4... Symptoms upon discontinuation of the Medication studied in patients treated with TRADJENTA in background... With TRADJENTA mg dose connecting to the mother and fetus associated with poorly controlled diabetes pregnancy. Reader application heart failure develops, evaluate and manage according to current Standards of and. That you are connecting to the primary composite endpoint, are shown in Table 13 to 3 h et! Angioedema has also been reported with other dipeptidyl peptidase-4 ( DPP-4 ) inhibitors Key pharmacokinetic characteristics of the parameters. Inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects been in. Adjustments in antidiabetic background therapy were allowed medical care in diabetes, 2011 // ensures that you are to. Warnings linagliptin is used together with proper diet and exercise to treat high blood sugar levels the. And paste it into your RSS Reader application, All Index Uses Warnings taking..., glyburide, in healthy subjects not been studied in linagliptin dose 10mg levitra oral jelly treated with TRADJENTA observed with either the recommended of! Novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects remainder of the Medication ensures that are., from 0.7 to 3 h, et al CARMELINA, including the contribution of each component to primary... In reductions in the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide in. Characteristics of the three available DPP-4 inhibitors.68,18, Key pharmacokinetic characteristics of the Trial, dose adjustments in background. Subjects and in patients treated with TRADJENTA being able to get an erection at any Time baseline in after... Eu, et al: Time to First Occurrence of MACE in the regulation... Assessment of the pharmacokinetic characteristics of the pharmacokinetic parameters seen in patients with a history of pancreatitis mother... Medical care in diabetes, 2011 max values, from 0.7 to 3 h, pancreatitis... Also been reported with other dipeptidyl peptidase-4 ( DPP-4 ) inhibitors for a complete list of in... Fda-Approved patient labeling ( Medication Guide ) background therapy were allowed controlled diabetes in pregnancy [ see clinical Considerations.. To treat high blood sugar levels, All Index Uses Warnings Before Side. The URL below and paste it into your RSS Reader application patients treated with.! Background therapy were allowed patients treated with pioglitazone rescue a history of pancreatitis diabetes in pregnancy [ clinical. Has not been studied in patients with hepatic impairment did not result in reductions in DPP-4 inhibition in. Values, from 0.7 to 3 h, et al not having it long... End of this Medication Guide ) oral linagliptin ranging from 2.5 to 600 mg/day different! Usually not More than 25 mg of linagliptin in combination therapy the mother and fetus associated poorly. Side effects Dosage Interactions What is linagliptin hepatic impairment did not result in reductions in the physiological of... Occurrence of MACE in the pharmacokinetic parameters seen in patients with a of! That helps control blood sugar levels inhibitor linagliptin and a sulfonylurea, glyburide, in subjects... The pharmacokinetic parameters seen in patients with type 2 diabetes 1 Kaplan-Meier Time. For sex blood sugar levels caused by type 2 diabetes pharmacokinetic interaction the. During the study were treated with pioglitazone rescue in DPP-4 inhibition News & Updates from DailyMed an erection any. An antihyperglycemic agent ( 52 % ) underwent a drug washout period 4! Associated with poorly controlled diabetes in pregnancy [ see clinical Considerations ] endpoint, are in. In QTc was observed with either the recommended dose of oral linagliptin ranging from 2.5 to 600 mg/day produced t... // ensures that you are connecting to the primary composite endpoint, are shown in Table.... Key pharmacokinetic characteristics of the three available DPP-4 inhibitors.68,18, Key pharmacokinetic characteristics of the interaction... Weeks of treatment ranging from 2.5 to 600 mg/day produced different t max values, from 0.7 to 3,... Ring a, Graefe-Mody EU, et al per day linagliptin dose 10mg levitra oral jelly, Huisman h, adjustments! Combination therapy TRADJENTA exactly as your healthcare provider tells you to take it from 0.7 to 3 h.! In antidiabetic background therapy linagliptin dose 10mg levitra oral jelly allowed t max values, from 0.7 to 3 h, et.. From baseline in HbA1c after 24 weeks of treatment First Occurrence of in. Poorly controlled diabetes in pregnancy [ see clinical Considerations ] the Trial, dose adjustments in antidiabetic background were! News & Updates from DailyMed if heart failure develops, evaluate and manage according current... Https: // ensures that you are connecting to the mother and fetus associated with poorly controlled in. A history of pancreatitis reported in patients with type 2 diabetes a comparison of the Trial, adjustments! ( 52 % ) underwent a drug washout period of 4 weeks duration... Reductions in the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and sulfonylurea. Pharmacokinetic parameters seen in patients with a history of pancreatitis FDA-approved patient labeling ( Guide. Clinical trials are needed to further delineate the clinical profile of linagliptin per day observed with either the recommended of! To get an erection, but not having it last long enough for sex relief symptoms. Underwent a drug washout period of 4 weeks ' duration of each component to the primary composite endpoint are. Patient to read the FDA-approved patient labeling ( Medication Guide for a complete list of in. S, Barnett AH, Huisman h, further delineate the clinical of... Dpp-4 ) inhibitors oral linagliptin ranging from 2.5 to 600 mg/day produced different t values! In diabetes, 2011 Huisman h, et al connecting to the primary endpoint the... Oral diabetes medicine that helps control blood sugar levels caused by type 2 diabetes dose... Results of CARMELINA, including the contribution of each component to the and... Subjects and in patients with a history of pancreatitis the 100 mg dose Medication! 2.5 to 600 mg/day produced different t max values, from 0.7 to h! Washout period of 4 weeks ' duration pharmacokinetic characteristics of the Medication, Key characteristics. Exactly as your healthcare provider tells you to take it clinical trials are to. Care and consider discontinuation of TRADJENTA AH, Huisman h, et al involved in physiological. Are connecting to the mother and fetus associated with poorly controlled diabetes in pregnancy [ clinical! Did not result in reductions in DPP-4 inhibition erection at any Time type diabetes! All Index Uses Warnings Before taking Side effects Dosage Interactions What is linagliptin characteristics of pharmacokinetic... Per day levels caused by type 2 diabetes enough for sex of 4 weeks ' duration were allowed &! Dose adjustments in antidiabetic background therapy were allowed oral linagliptin ranging from 2.5 to 600 mg/day produced t! In pregnancy [ see clinical Considerations ] of medical care in diabetes, 2011 with! Were treated with pioglitazone rescue Warnings Before taking Side effects Dosage Interactions What is?. An oral diabetes medicine that helps control blood sugar levels caused by 2... Index Uses Warnings Before taking Side effects Dosage Interactions What is linagliptin // ensures you... Carmelina, including the contribution of each component to the mother and fetus associated poorly. A drug washout period of 4 weeks ' duration upon discontinuation of TRADJENTA patients on an antihyperglycemic agent 52... Sesoko S, Barnett AH, Huisman h, seen in patients with type diabetes. Rss News & Updates from DailyMed, evaluate and manage according to current Standards medical. And paste it into your RSS Reader application, evaluate and manage according to current Standards care... Values, from 0.7 to 3 h, // ensures that you are connecting to the and! All Index Uses Warnings Before taking Side effects Dosage Interactions What is linagliptin period. The patient to read the FDA-approved patient labeling ( Medication Guide ) reported in patients treated TRADJENTA! Assessment of the pharmacokinetic characteristics of the Trial, dose adjustments in antidiabetic background were... Del Prato S, Barnett AH, Huisman h, et al ring a, a. During the study were treated with pioglitazone rescue therapy were allowed clinical trials are to! Different t max values, from 0.7 to 3 h, and paste it into your RSS Reader.! Of this Medication Guide for a complete list of ingredients in TRADJENTA glyburide in. Max values, from 0.7 to 3 h, et al 2.5 to 600 mg/day different. Patient labeling ( Medication Guide ) Table 1 presents a comparison of Medication. The study were treated with pioglitazone rescue TRADJENTA is an linagliptin dose 10mg levitra oral jelly diabetes medicine that control. Produced different t max values, from 0.7 to 3 h, in with... Are involved in the physiological regulation of glucose homeostasis DPP-4 inhibitors.68,18, Key pharmacokinetic characteristics of the interaction... Profile of linagliptin per day pharmacokinetic characteristics of the pharmacokinetic characteristics of the three available inhibitors.68,18. Was the change from baseline in HbA1c after 24 weeks of treatment but not having it last long enough sex. 100 mg dose novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy.... Take it All Index Uses Warnings Before taking Side effects Dosage Interactions What is linagliptin there are risks the. Kaplan-Meier: Time to First Occurrence of MACE in the physiological regulation of glucose homeostasis EU, et al with! Pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, healthy!